Estrogen receptor (ER), progesterone-receptor (PR) and HER2, routinely available in BC tissue samples and recorded in cancer registries and patients’ medical records, are useful tools for therapeutic decision making and could be considered reliable surrogates for the more expensive molecular subtyping [14]. This evidence concerns the gene PGR and breast cancer.